StockNews.AI
MGRM
StockNews.AI
36 days

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRM, WAT, SONN on Behalf of Shareholders

1. MGRM is selling to Zimmer Biomet for $4.04 per share. 2. Shareholders may receive additional $12.37 per share based on milestones. 3. Halper Sadeh LLC investigates potential shareholder violations regarding the transaction. 4. Investors may explore legal rights concerning the sale. 5. Implications of shareholder actions could impact the transaction's completion.

5m saved
Insight
Article

FAQ

Why Neutral?

The proposed sale price is below the expected future valuation, creating uncertainty. Historical examples show that similar investigations can lead to either improved offers or delays.

How important is it?

The potential for improved shareholder compensation directly impacts MGRM's share price performance. Legislative scrutiny can modify terms of the sale, affecting investor sentiment.

Why Short Term?

The investigation focuses on immediate legal concerns that could influence negotiation outcomes soon. Similar past cases have often resolved in weeks to months.

Related Companies

Halper Sadeh LLC Investigates Companies for Securities Violations

NEW YORK, July 14, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Monogram Technologies Inc. (NASDAQ: MGRM)

Monogram's sale to Zimmer Biomet Holdings, Inc. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash if certain product development, regulatory and revenue milestones are achieved through 2030. If you are a Monogram shareholder, click here to learn more about your legal rights and options.

Waters Corporation (NYSE: WAT)

Waters' merger with BD and Company's Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholders are expected to own approximately 60.8% of the combined company. If you are a Waters shareholder, click here to learn more about your rights and options.

Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

Sonnet's merger with Rorschach I LLC. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. If you are a Sonnet shareholder, click here to learn more about your legal rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email example@email.com or example@email.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
example@email.com
example@email.com
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Related News